Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169)

November 25, 2020 updated by: Bristol-Myers Squibb

Expanded Access Program With Nivolumab Monotherapy in Subjects With Advanced or Metastatic Squamous (Sq) or Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimens for the Treatment of Stage IIIb/IV SqNSCLC

The purpose of this study is to provide treatment with nivolumab, a fully human monoclonal antibody, to subjects who have relapsed after treatment with a minimum of 1 prior systemic treatment for advanced or metastatic squamous (Sq) or non-squamous (non-Sq) non-small cell lung cancer (NSCLC) , Stage IIIB/IV and whose physicians believe that nivolumab treatment is appropriate.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
No longer available

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Expanded Access

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
      • Rio de Janeiro, Brazil, 22793
        • Local Institution
      • Rio de Janeiro, Brazil
        • Local Institution
      • Salvador, Brazil, 40170
        • Local Institution
      • São Paulo, Brazil, 01308
        • Local Institution
      • São Paulo, Brazil, 01321
        • Local Institution
      • São Paulo, Brazil, 01406
        • Local Institution
      • São Paulo, Brazil, 01525
        • Local Institution
      • São Paulo, Brazil, 03102
        • Local Institution
      • São Paulo, Brazil, 04538
        • Local Institution
      • São Paulo, Brazil, 05651
        • Local Institution
    • Ceará
      • Fortaleza, Ceará, Brazil, 60130
        • Local Institution
      • Fortaleza, Ceará, Brazil, 60336
        • Local Institution
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brazil, 41950
        • Local Institution
    • Federal District
      • Brasília, Federal District, Brazil, 70200
        • Local Institution
      • Distrito Federal, Federal District, Brazil, 72025
        • Local Institution
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brazil, 30430
        • Local Institution
    • Paraná
      • Cascavel, Paraná, Brazil, 85806
        • Local Institution
      • Curitiba, Paraná, Brazil, 80530
        • Local Institution
      • Curitiba, Paraná, Brazil
        • Local Institution
    • Pernambuco
      • Recife, Pernambuco, Brazil, 50070
        • Local Institution
      • Recife, Pernambuco, Brazil, 52010
        • Local Institution
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brazil, 59062
        • Local Institution
    • Rio Grande do Sul
      • Ijuí, Rio Grande do Sul, Brazil
        • Local Institution
      • Passo Fundo, Rio Grande do Sul, Brazil, 99010
        • Local Institution
      • Porto Alegre, Rio Grande do Sul, Brazil
        • Local Institution
      • Porto Alegre, Rio Grande do Sul, Brazil, 90020
        • Local Institution
      • Porto Alegre, Rio Grande do Sul, Brazil, 90035
        • Local Institution
      • Porto Alegre, Rio Grande do Sul, Brazil, 90470
        • Local Institution
    • Santa Catarina
      • Florianópolis, Santa Catarina, Brazil, 88034
        • Local Institution
      • Itajaí, Santa Catarina, Brazil, 88301
        • Local Institution
    • São Paulo
      • Barretos, São Paulo, Brazil, 14784
        • Local Institution
      • Campinas, São Paulo, Brazil, 13092
        • Local Institution
      • Jaú, São Paulo, Brazil, 17210
        • Local Institution
      • Ribeirão Preto, São Paulo, Brazil, 14025
        • Local Institution
      • Santo André, São Paulo, Brazil, 09060
        • Local Institution
  • Canada
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Local Institution
    • British Columbia
      • Burnaby, British Columbia, Canada, V5G 2X6
        • Local Institution
      • Kelowna, British Columbia, Canada, V1Y 5L3
        • Local Institution
      • Richmond, British Columbia, Canada, V6X 1A2
        • Local Institution
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0V9
        • Local Institution
    • New Brunswick
      • Moncton, New Brunswick, Canada, E1C 2Z3
        • Local Institution
    • Ontario
      • Greater Sudbury, Ontario, Canada, P3E 5J1
        • Local Institution
      • Hamilton, Ontario, Canada
        • Local Institution
      • Oshawa, Ontario, Canada, L1G 2B9
        • Local Institution
      • Thunder Bay, Ontario, Canada, P7B 6V4
        • Local Institution
      • Toronto, Ontario, Canada, M4N 3M5
        • Local Institution
    • Quebec
      • Chicoutimi, Quebec, Canada, G7H 2A4
        • Local Institution
      • Greenfield Park, Quebec, Canada, J4V 2H1
        • Local Institution
      • Montreal, Quebec, Canada, H3A 1A1
        • Local Institution
      • Rimouski, Quebec, Canada, G5L 5T1
        • Centre De Sante Et De Services Sociaux Rimouski Neigette

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Description

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Sq or Non-Sq NSCLC, Stage IIIb/IV (histologically or cytologically confirmed)
  • Relapsed after 1 prior platinum-based systemic treatment
  • Eastern Cooperative Oncology Group (ECOG) Performance Status < 2
  • CNS metastasis must be treated and returned to baseline at least 2 weeks before first dose of nivolumab and off steroids or using stable or decreasing dose of < 10 mg prednisone or equivalent
  • Prior chemotherapy, Tyrosine Kinase Inhibitor (TKI) therapy or Immunotherapy (tumor vaccine, cytokine or growth factor to control cancer) must be completed at least 2 weeks before first nivolumab dose

Exclusion Criteria:

  • CNS metastases (untreated and/or symptomatic)
  • Carcinomatous meningitis
  • ECOG Performance status > 3
  • Corticosteroids > 10 mg prednisolone/day (or equivalent)
  • Prior treatment with anti-PD-1, anti-PD-L-1, anti-PDL2, anti-CT137 or anti-CTLA antibody, including ipilimumab or any other drugs specifically targeting T cell costimulation or checkpoint pathways

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bristol-Myers Squibb

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 16, 2015

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 16, 2015

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 18, 2015

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 27, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 25, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CA209-169

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Non-squamous Non-Small Cell Lung Cancer

Clinical Trials on Nivolumab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings